Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.
Advances in anti-BRAF therapies for lung cancer / Roviello, Giandomenico; D'Angelo, Alberto; Sirico, Marianna; Pittacolo, Matteo; Conter, Felipe Umpierre; Sobhani, Navid. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 0167-6997. - STAMPA. - 39:(2021), pp. 879-890. [10.1007/s10637-021-01068-8]
Advances in anti-BRAF therapies for lung cancer
Roviello, Giandomenico
;
2021
Abstract
Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.